NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDA
Post# of 66
(Total Views: 290)
Posted On: 10/29/2020 4:30:52 PM
NetworkNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Talks Porcine Usage, Producing Synthetic Alternative
AzurRx BioPharma (NASDAQ: AZRX), a New York-based biopharmaceutical company specializing in the development of therapeutic proteins for the treatment of patients with gastrointestinal disorders, recently talked about its usage of porcine (pig) products in its production of pharmaceuticals and medicinals. Included in the discussion was a look at the disadvantages of such usage. AzurRx noted that pigs have been used for centuries in medical research and development; in fact, one study noted that pigs had been used in an estimated 20 medications and pharmaceuticals including six for the pancreas, which are of particular interest for AZRX. There are downsides to such usage, the company noted, including supply chain, concentration and purity issues. Because of these issues, AzurRx is hoping to develop synthetic replacement products. One of AZRX’s most promising treatments is MS1819, a lead product candidate being studied for the treatment of exocrine pancreatic insufficiency (“EPI”) associated with cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). The company is currently involved in several clinical trials for the drug, including two trial sites that were recently activated in Turkey. “We are truly pleased and encouraged by the interest in our expanding global Phase 2 Combination Trial,” AzurRx chief medical officer Dr. James Pennington stated in the press release. “The recently reported interim data suggests promising results, and the full data readout is expected in the second quarter of next year. Our investigators in Turkey have been extremely diligent in driving the startup of this trial in a very efficient and effective manner, and we look forward to our continued work with them.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
AzurRx BioPharma (NASDAQ: AZRX), a New York-based biopharmaceutical company specializing in the development of therapeutic proteins for the treatment of patients with gastrointestinal disorders, recently talked about its usage of porcine (pig) products in its production of pharmaceuticals and medicinals. Included in the discussion was a look at the disadvantages of such usage. AzurRx noted that pigs have been used for centuries in medical research and development; in fact, one study noted that pigs had been used in an estimated 20 medications and pharmaceuticals including six for the pancreas, which are of particular interest for AZRX. There are downsides to such usage, the company noted, including supply chain, concentration and purity issues. Because of these issues, AzurRx is hoping to develop synthetic replacement products. One of AZRX’s most promising treatments is MS1819, a lead product candidate being studied for the treatment of exocrine pancreatic insufficiency (“EPI”) associated with cystic fibrosis (“CF”) and chronic pancreatitis (“CP”). The company is currently involved in several clinical trials for the drug, including two trial sites that were recently activated in Turkey. “We are truly pleased and encouraged by the interest in our expanding global Phase 2 Combination Trial,” AzurRx chief medical officer Dr. James Pennington stated in the press release. “The recently reported interim data suggests promising results, and the full data readout is expected in the second quarter of next year. Our investigators in Turkey have been extremely diligent in driving the startup of this trial in a very efficient and effective manner, and we look forward to our continued work with them.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)